Importance of the organ-independent elimination of cisatracurium

Anesthesia and Analgesia

Volumn 83, Issue 5, 1996, Pages 1065-1071

  Kisor, David F ^a   Schmith, Virginia D ^b   Wargin, William A ^b   Lien, Cynthia A ^b   Ornstein, Eugene ^b   Cook, D Ryan ^b  

^a GLAXOSMITHKLINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATRACURIUM; ATRACURIUM BESILATE; CISATRACURIUM; DIAZEPAM; FENTANYL; ISOFLURANE; LIDOCAINE; MIDAZOLAM; NEUROMUSCULAR BLOCKING AGENT; SUXAMETHONIUM; THIOPENTAL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROMUSCULAR BLOCKING; PLASMA CLEARANCE; PRIORITY JOURNAL;

ADULT; ATRACURIUM; FEMALE; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; ISOQUINOLINES; KIDNEY; LIVER; MALE; METABOLIC CLEARANCE RATE; MODELS, CHEMICAL; NEUROMUSCULAR BLOCKING AGENTS; TEMPERATURE; TISSUE DISTRIBUTION;

EID: 0029952949     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199611000-00029     Document Type: Article

References (25)

1. Stenlake JB, Waigh RD, Dewar GH, et al. Biodegradable neuromuscular blocking agents. 6. Stereochemical studies on atra- curium and related polyalkylene di-esters. Eur J Med Chem 1984;19:441-50.
2. Belmont MR, Lien CA, Quessy S, et al. The clinical neuromus- cular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995;82:1139-45.
3. Lepage JY, Malinovsky JM, Malinge M, et al. Comparison of equipotent doses of 51W89 and atracurium [abstract]. Anesthesiology 1994;81(3A):A1090.
4. Lien CA, Belmont MR, Abalos A, et al. The cardiovascular effects and histamine releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995;82:1131-8.
5. Lapage J, Malinovsky M, Cozian A, Finaud M. 51W89: dose-response, neuromuscular blocking profile, and cardiovascular effects [abstract]. Anesthesiology 1993;79:A945.
6. Welch R, Brown A, Dahl R. The in vitro degradation of cisatracurium, the R, Cis-R',Cis isomer of atracurium, in human and rat plasma. Clin Pharmacol Ther 1995;58:132-42.
7. Stiller RL, Cook DR, Chakravorti S. In vitro degradation of atracurium in human plasma. Br J Anaesth 1985;57:1085-8.
8. Fisher DM, Canfell PC, Fahey MR, et al. Elimination of atracurium in humans: Contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination. Anesthesiology 1986;65:6-12.
9. Fahey MR, Rupp SM, Fisher DM, et al. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 1984;61:699-702.
10. Ward S, Neill EAM. Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure). Br J Anaesth 1983;55:1169-72.
11. Hull CJ. A model for atracurium? [Editorial]. Br J Anaesth 1983;55:95-6.
12. Lien CA, Schmith VD, Belmont MR, et al. Pharmacokinetics of cisatracurium in patients receiving opioid anesthesia. Anesthesiology 1996;84:300-8.
13. Ornstein E, Lien C, Matteo RS, et al. Pharmacodynamics and pharmacokinetics of 51W89 in geriatric patients. Anesthesiology 1996;84:520-5.
14. DeWolf AM, Freeman JA, Scott VL, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth 1996;76:624-8.
15. Peck C, Conner DP, Murphy MG. Bedside estimation of ideal body weight. In: Peck C, Conner DP, Murphy MG, eds. Bedside clinical pharmacokinetics. Vancouver: Applied Therapeutics Inc., 1989:80.
16. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
17. Riegelman S, Loo JCK, Rowland M. Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. J Pharm Sci 1968;57:117-23.
18. Metzler CM, Elfring GL, McEwen AJ. A package of computer programs for pharmacokinetic modeling [abstract]. Biometrics 1974;30:562.
19. Nakashima E, Benet LZ. General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment. J Pharmacokinet Biopharm 1988;16:475-92.
20. Blum MR, Liao SHT, Hajian G. Consideration of linear regression with errors in both variables as applied to clinical pharmacokinetics. In: Benet LZ, Levy G, Ferraiolo BL, eds. Pharmacokinetics: a modern view. New York: Plenum Press, 1984:422-5.
21. Riggs DS, Guarnieri JA, Addelman S. Fitting straight lines when both variables are subject to error. Life Sci 1978;22:1305-60.
22. Tsui D, Graham GG, Torda TA. The pharmacokinetics of atracurium isomers in vitro and in humans. Anesthesiology 1987;67:722-8.
23. Ward S, Boheimer N, Weatherley BC, et al. Pharmacokinetics of atracurium and its metabolites in patients with normal renal function, and in patients with renal failure. Br J Anaesth 1987;59:697-706.
24. Parker CJR, Hunter JM. Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis. Br J Anaesth 1989;62:177-83.
25. Donati F, Varin F, Ducharme J, et al. Pharmacokinetics and pharmacodynamics of atracurium obtained with arterial and venous blood samples. Clin Pharmacol Ther 1991;49:515-22.